DOD Prostate Cancer, Idea Development Award | W81XWH 19 PCRP IDA

Opportunity Information: Apply for W81XWH 19 PCRP IDA

The DOD Prostate Cancer Research Program (PCRP) Idea Development Award (Funding Opportunity Number W81XWH-19-PCRP-IDA) is a competitive research grant/cooperative agreement designed to fund genuinely new, creative prostate cancer research ideas that could meaningfully move the field forward. The central aim is to stimulate innovation rather than support routine next-step studies, and applicants are expected to clearly explain how their concept could advance the PCRP mission and ultimately improve outcomes for patients, including relevance to active duty Service members, Veterans, military beneficiaries, and the broader American public.

A defining feature of this opportunity is its emphasis on innovation. Proposed work is expected to introduce a fresh approach, such as creating a new scientific or clinical paradigm, challenging an existing assumption, approaching a stubborn problem from an unusual angle, or leveraging a unique study population or dataset in a way that others have not. Multidisciplinary concepts are specifically encouraged, and proposals that simply extend published findings in an incremental way are explicitly not viewed as innovative enough for this mechanism. In practical terms, reviewers are looking for projects that take smart risks grounded in strong reasoning and a clear vision for how the idea could change research directions or clinical thinking.

Impact is treated as equally important as innovation. Applications must directly address at least one FY19 PCRP Overarching Challenge and explain, in plain and convincing terms, what problem is being solved and why success would matter. Strong applications lay out both near-term impact (for example, generating a tool, dataset, biomarker lead, or mechanistic insight that quickly enables downstream work) and long-term impact (such as shifting treatment strategies, enabling better risk stratification, or informing prevention and survivorship approaches). The program is not just funding interesting biology; it is funding ideas that can plausibly lead to meaningful advances in prostate cancer research and/or patient care.

Preliminary data are encouraged but not required, which is important because the award is meant to make space for earlier-stage, high-creativity concepts. If preliminary data are included, they should come from the Principal Investigator (PI) or the research team and can be unpublished. Even without preliminary results, proposals still need a solid scientific rationale supported by careful logic and a credible reading of the literature, so that the idea feels bold but not speculative in a careless way.

The announcement strongly pushes applicants to build studies that are rigorous and positioned for translation. It highlights expectations such as authenticating cell lines, applying statistical rigor in animal and epidemiological work, and including experiments that test clinical relevance and translatability, ideally with validation in patient cohorts when feasible. Applicants are also encouraged to consider major PCRP-supported resources if human specimens or linked clinical data are essential, especially the Prostate Cancer Biorepository Network (PCBN) and the North Carolina-Louisiana Prostate Cancer Project (PCaP). More broadly, the program welcomes studies that mine large patient datasets with long-term records and biospecimens, especially when paired with modern genomics/proteomics, bioinformatics, and mathematical modeling that can extract clinically useful insight.

The mechanism includes a New Investigator category intended to help early-career faculty or investigators building independence compete in a separate pool from more established applicants. New Investigators must meet specific eligibility criteria (spelled out in the full announcement) and are required to include at least one collaborator with demonstrated prostate cancer research experience, backed by a track record of funding and publications. The PI is expected to explain how that collaboration fills gaps in expertise and strengthens the team’s ability to answer the proposed question.

Team science is welcome, including multi-institutional projects, but coordination has to be explicit rather than assumed. Applications involving multiple organizations must include a clear plan for how partners will communicate, coordinate progress, share results, and transfer data. They also must include an intellectual property plan that anticipates and resolves potential IP or material transfer barriers, with the goal of preventing institutional friction from undermining collaboration and slowing progress.

Human subjects research is allowed, but clinical trials are not. The program uses a specific FY19 definition of a clinical trial focused on prospective assignment of human subjects to interventions to evaluate health outcomes, and projects fitting that definition are not permitted under this award. That said, correlative studies tied to an existing clinical trial are encouraged when they are no greater than minimal risk, and they must satisfy both local IRB review and DOD-specific human research oversight through the USAMRMC Office of Research Protections (ORP), Human Research Protection Office (HRPO). Applicants should plan for HRPO review timelines (often 2 to 3 months or more) and understand that DOD requirements can demand additional documentation beyond what a typical IRB requires. Studies involving recruitment must also provide quarterly enrollment targets and will be managed with recruitment milestones as part of continued project support.

Animal research is permitted but also comes with layered oversight. In addition to local IACUC review, funded projects must be reviewed and approved by the USAMRMC ORP Animal Care and Use Review Office (ACURO) before animal work begins, with similar expectations for review timelines. The announcement reinforces expectations for reproducible, well-reported preclinical research, pointing applicants toward widely used standards for rigor (randomization, blinding, sample-size estimation, transparent data handling) and reporting guidance such as ARRIVE.

If investigators need access to DOD or VA populations, records, databases, space, or equipment, the application is expected to describe that access up front and include documentation such as letters of support from the appropriate authority. The guidance is clear that some resources may only be accessible through collaboration with a DOD or VA investigator who plays a meaningful role. If access cannot be confirmed, the government may delay, withdraw, or revoke funding until access is adequately demonstrated, so applicants are incentivized to lock down feasibility early.

From a funding and administrative standpoint, awards are made by the Department of Defense (Department of the Army, USAMRAA) as assistance agreements, meaning either grants or cooperative agreements depending on how much substantial involvement by the DOD is anticipated during performance. Budget caps for direct costs across the full period of performance are set at $600,000 for New Investigators and $750,000 for Established Investigators. For FY19, the program planned to allocate about $35.52 million total to fund roughly 12 New Investigator awards and 20 Established Investigator awards, with final selections dependent on federal funds availability and the outcome of scientific and programmatic review. The solicitation originally closed September 19, 2019, with awards anticipated no later than September 30, 2020, and FY19 funds expected to remain available for use only through September 30, 2025.

Overall, the Idea Development Award is best understood as a high-bar innovation mechanism: it favors original, multidisciplinary concepts with a clear line of sight to significant impact on major prostate cancer challenges, expects thoughtful study design that holds up under scrutiny, allows (but does not require) preliminary data, prohibits clinical trials while permitting appropriately overseen human subjects and correlative work, and provides distinct lanes for New vs. Established investigators with substantial direct-cost support to develop and validate promising new directions.

• The Department of Defense, Dept. of the Army -- USAMRAA in the science and technology and other research and development sector is offering a public funding opportunity titled "DOD Prostate Cancer, Idea Development Award" and is now available to receive applicants.
• Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 12.420.
• This funding opportunity was created on Apr 05, 2019.
• Applicants must submit their applications by Sep 19, 2019. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
• The number of recipients for this funding is limited to 12 candidate(s).
• Eligible applicants include: Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled Additional Information on Eligibility.

Apply for W81XWH 19 PCRP IDA

[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal: